The emergence of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable excitement within the medical community. This novel dual GIP and GLP-1 agonist medication suggests to provide impressive improvements in body reduction compared to existing therapies. Preliminary clinical data have indicated significant declines in body fat percenta